392 related articles for article (PubMed ID: 21740361)
1. Attenuated oncolytic measles virus strains as cancer therapeutics.
Msaouel P; Iankov ID; Dispenzieri A; Galanis E
Curr Pharm Biotechnol; 2012 Jul; 13(9):1732-41. PubMed ID: 21740361
[TBL] [Abstract][Full Text] [Related]
2. Opportunities to debottleneck the downstream processing of the oncolytic measles virus.
Loewe D; Dieken H; Grein TA; Weidner T; Salzig D; Czermak P
Crit Rev Biotechnol; 2020 Mar; 40(2):247-264. PubMed ID: 31918573
[TBL] [Abstract][Full Text] [Related]
3. Potential and clinical translation of oncolytic measles viruses.
Robinson S; Galanis E
Expert Opin Biol Ther; 2017 Mar; 17(3):353-363. PubMed ID: 28129716
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic measles virus strains as novel anticancer agents.
Msaouel P; Opyrchal M; Domingo Musibay E; Galanis E
Expert Opin Biol Ther; 2013 Apr; 13(4):483-502. PubMed ID: 23289598
[TBL] [Abstract][Full Text] [Related]
5. Mitophagy enhances oncolytic measles virus replication by mitigating DDX58/RIG-I-like receptor signaling.
Xia M; Gonzalez P; Li C; Meng G; Jiang A; Wang H; Gao Q; Debatin KM; Beltinger C; Wei J
J Virol; 2014 May; 88(9):5152-64. PubMed ID: 24574393
[TBL] [Abstract][Full Text] [Related]
6. Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview.
Msaouel P; Dispenzieri A; Galanis E
Curr Opin Mol Ther; 2009 Feb; 11(1):43-53. PubMed ID: 19169959
[TBL] [Abstract][Full Text] [Related]
7. Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects.
Msaouel P; Opyrchal M; Dispenzieri A; Peng KW; Federspiel MJ; Russell SJ; Galanis E
Curr Cancer Drug Targets; 2018; 18(2):177-187. PubMed ID: 28228086
[TBL] [Abstract][Full Text] [Related]
8. Measles virus as an oncolytic vector platform.
Blechacz B; Russell SJ
Curr Gene Ther; 2008 Jun; 8(3):162-75. PubMed ID: 18537591
[TBL] [Abstract][Full Text] [Related]
9. [Synergistic Effect of NF-κB Signaling Pathway Inhibitor and Oncolytic
Measles Virus Vaccine Strain against Lung Cancer and Underlying Mechanisms].
Xia M; Meng G; Dong J
Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):245-253. PubMed ID: 33775041
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic measles virus retargeting by ligand display.
Msaouel P; Iankov ID; Allen C; Russell SJ; Galanis E
Methods Mol Biol; 2012; 797():141-62. PubMed ID: 21948475
[TBL] [Abstract][Full Text] [Related]
11. Measles to the Rescue: A Review of Oncolytic Measles Virus.
Aref S; Bailey K; Fielding A
Viruses; 2016 Oct; 8(10):. PubMed ID: 27782084
[TBL] [Abstract][Full Text] [Related]
12. Engineered measles virus as a novel oncolytic therapy against prostate cancer.
Msaouel P; Iankov ID; Allen C; Morris JC; von Messling V; Cattaneo R; Koutsilieris M; Russell SJ; Galanis E
Prostate; 2009 Jan; 69(1):82-91. PubMed ID: 18973133
[TBL] [Abstract][Full Text] [Related]
13. Enhanced killing of therapy-induced senescent tumor cells by oncolytic measles vaccine viruses.
Weiland T; Lampe J; Essmann F; Venturelli S; Berger A; Bossow S; Berchtold S; Schulze-Osthoff K; Lauer UM; Bitzer M
Int J Cancer; 2014 Jan; 134(1):235-43. PubMed ID: 23797800
[TBL] [Abstract][Full Text] [Related]
14. Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment.
Sugiyama T; Yoneda M; Kuraishi T; Hattori S; Inoue Y; Sato H; Kai C
Gene Ther; 2013 Mar; 20(3):338-47. PubMed ID: 22717740
[TBL] [Abstract][Full Text] [Related]
15. Virotherapy--cancer targeted pharmacology.
Tedcastle A; Cawood R; Di Y; Fisher KD; Seymour LW
Drug Discov Today; 2012 Mar; 17(5-6):215-20. PubMed ID: 22198165
[TBL] [Abstract][Full Text] [Related]
16. [Measles virus: a future therapeutic agent in oncology?].
Touchefeu Y; Schick U; Harrington KJ
Med Sci (Paris); 2012 Apr; 28(4):388-94. PubMed ID: 22549866
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic potential of oncolytic measles virus: promises and challenges.
Galanis E
Clin Pharmacol Ther; 2010 Nov; 88(5):620-5. PubMed ID: 20881957
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic measles viruses for cancer therapy.
Nakamura T; Russell SJ
Expert Opin Biol Ther; 2004 Oct; 4(10):1685-92. PubMed ID: 15461580
[TBL] [Abstract][Full Text] [Related]
19. Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination.
Baldo A; Galanis E; Tangy F; Herman P
Hum Vaccin Immunother; 2016 May; 12(5):1102-16. PubMed ID: 26631840
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic measles virus strains in the treatment of gliomas.
Allen C; Paraskevakou G; Liu C; Iankov ID; Msaouel P; Zollman P; Myers R; Peng KW; Russell SJ; Galanis E
Expert Opin Biol Ther; 2008 Feb; 8(2):213-20. PubMed ID: 18194077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
